Do AML Bone Marrow Biopsies Show Racial and Ethnic Variances?
https://vimeo.com/948960333 Are racial and ethnic differences shown in acute myeloid leukemia (AML) bone marrow biopsies? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses what early AML studies…
How Bone Marrow Biopsies Impact Acute Myeloid Leukemia Treatment and Care
https://vimeo.com/948960365 How are acute myeloid leukemia (AML) treatment and care impacted by bone marrow biopsies? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School explains the role that bone…
Novel AML Therapy Use | Impact of Socioeconomic Status and Other Factors
https://vimeo.com/948960382 How do socioeconomic status and other factors impact novel acute myeloid leukemia (AML) therapy use? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses major factors that…
Underrepresented AML Clinical Trial Groups | What Solutions Are Underway?
https://vimeo.com/948960402 What steps are being taken to help underrepresented acute myeloid leukemia (AML) clinical trial groups? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses an important approach…
Why Is Post-Access Enrollment Vital in AML Clinical Trial Participation?
https://vimeo.com/948960428 For acute myeloid leukemia (AML) clinical trial participation, what makes post-access enrollment essential? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that play into post-access…
What AML Clinical Trial Inequities Do Minority and Ethnic Groups Face?
https://vimeo.com/948960457 Do minority and ethnic groups face acute myeloid leukemia (AML) clinical trial inequities? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses research study results of NCI-designated…
What Are Key Acute Myeloid Leukemia Care Barriers and Solutions?
https://vimeo.com/948960484 What are key barriers and solutions to acute myeloid leukemia (AML) care? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that create AML care barriers,…
Dr. Andrew Hantel: Why Is It Important for You to Empower Patients?
Dr. Andrew Hantel: Why Is It Important for You to Empower Patients? from Patient Empowerment Network on Vimeo. How does Dr. Andrew Hantel empower his patients in their treatment decisions?…
What Are Myeloma Risk Factors for Veterans and First Responders?
https://vimeo.com/944207734 Veterans and first responders may come into contact with myeloma risk factors, but what are they? Expert Dr. Krina Patel from The University of Texas MD Anderson Cancer Center…
What Are the Advantages of Seeking Care With a Lung Cancer Specialist?
https://vimeo.com/949270857 What are the benefits of seeing a lung cancer specialist? Dr. Thomas Marron discusses the key advantages of specialty care, the value of a second opinion, and options for…
Lung Cancer Treatment Plan Advice | Where Do Clinical Trials Fit In?
https://vimeo.com/949270796 What questions should patients ask about a lung cancer treatment plan? Lung cancer expert Dr. Thomas Marron shares key considerations when choosing therapy and discusses where clinical trials fit…
Expert Perspective | New and Emerging Progress in Lung Cancer Treatment
https://vimeo.com/949270748 What’s the latest in lung cancer research? Dr. Thomas Marron from the Tisch Cancer Institute at Mount Sinai Hospital discusses the advances in targeted therapy and immunotherapy and what…